Biotechnology

Glycomimetics

GlycoMimetics Inc reports Q1 EPS loss of 4 cents

Glycomimetics released FY2025 Q1 earnings on May 14 (EST) with actual revenue of USD 0 and EPS of USD -3.6324

GlycoMimetics Terminates Cooperation and Licensing Agreement with APOLLOMICS

Glycomimetics released FY2024 Q4 earnings on February 13, 2025 (EST), with actual revenue of USD 0 and EPS of USD -11.2008

Glycomimetics released FY2024 earnings on February 13, 2025 (EST) with actual revenue of USD 0 and EPS of USD -58.7481

GlycoMimetics Inc CEO and CFO Resignation

Glycomimetics released FY2024 9 Months Earnings on November 13 (EST), Actual Revenue: USD 0, Actual EPS: USD -47.548

Glycomimetics released FY2024 Q3 earnings on November 13 (EST), actual revenue USD 0, actual EPS USD -15.2353

GLYCOMIMETICS reaches acquisition agreement with Crescent Biopharmaceuticals

Glycomimetics released FY2024 Q2 earnings on August 8, 2024 (EST), with actual revenue of USD 0 and EPS of USD -15.6557

Glycomimetics released FY2024 Semi-Annual Earnings on August 8, 2024 (EST), with actual revenue of USD 0 and EPS of USD -32.3125

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan, Laying Off Approximately 80% of Staff

Analysts initiate coverage on GlycoMimetics stock

Glycomimetics released FY2024 Q1 earnings on May 9 Pre-Market EST, actual revenue USD 0, actual EPS USD -16.657

HC Wainwright & Co. analyst Edward White downgrades GlycoMimetics (NASDAQ: GLYC) from Buy to Neutral

Glycomimetics released FY2023 earnings on March 27 (EST), actual revenue USD 10K, actual EPS USD -58.2538

Glycomimetics released FY2023 Q4 earnings on March 27, 2024 (EST) with actual revenue of USD 10K and EPS of USD -14.0986

Glycomimetics released FY2023 9 Months Earnings on November 3, 2023 (EST), with actual revenue of USD 0 and EPS of USD -44.3153

Glycomimetics released FY2023 Q3 earnings on November 3, 2023 (EST) with actual revenue of USD 0 and EPS of USD -14.3007

Glycomimetics released FY2023 Q2 earnings on August 2, 2023 (EST), with actual revenue of USD 0 and EPS of USD -12.849

Neuberger Berman Income Funds - Neuberger High Yield Strategies Fund Inc.

Snail

Mint Incorporation

Arrive AI

Avanos Medical

Ambitions Enterprise

ESH ACQUISITION CORP COM USD0.0001 CL A (S/R 13/06/2028)

Mega Fortune

Tradr 2X Long BE Daily ETF

Perfect Moment

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Glycomimetics(GLYC.US)

Glycomimetics Stock Performance Chart